LivePerson ups ATM program to $50M
LivePerson, Inc. is offering up to $50,000,000 of common stock pursuant to a sales agreement with A.G.P./Alliance Global Partners.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
LivePerson, Inc. is offering up to $50,000,000 of common stock pursuant to a sales agreement with A.G.P./Alliance Global Partners.
The supplement increases the prior aggregate program (previously $10,616,169) to $50,000,000, which includes 1,603,431 shares previously sold for an aggregate purchase price of $10,615,576. The supplement states there remains $39,384,424 available for sale from and after the date of this prospectus supplement dated February 26, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change does the LPCN prospectus supplement make to the existing offering?
How much capacity remains under the expanded LPCN at-the-market program?
Who is the sales agent for the LPCN at-the-market program?
Does the supplement indicate SEC approval of the securities for LPCN?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-275716
Prospectus Supplement
(To Prospectus Dated April 25, 2024)
Up to $50,000,000
of
Common Stock
This prospectus supplement amends and supplements the information in the prospectus supplement, dated April 26, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-275716) (the “Prior Prospectus”). This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.
Under the Prior Prospectus, we registered up to an aggregate of $10,616,169 of our common stock, $0.0001 par value per share, for offer and sale pursuant to a sales agreement, dated April 26, 2024, (the “Sales Agreement”), between us and A.G.P./Alliance Global Partners. From April 26, 2024 through the date of this prospectus supplement, we sold an aggregate of 1,603,431 shares of our common stock, for an aggregate purchase price of $10,615,576 under the Prior Prospectus. As of the date of this prospectus supplement, we are increasing the aggregate amount of common stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $50,000,000 of our common stock for sale under the Sales Agreement, including the shares of common stock previously sold, or $39,384,424 from and after the date hereof.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
A.G.P.
The date of this prospectus supplement is February 26, 2026.